NCT02668393 - Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2016

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Docetaxel

DRUG

Nintedanib

Low Dose

DRUG

Nintedanib

Medium dose

DRUG

Nintedanib

High dose

DRUG

Nintedanib

Continuous high dose

Trial Locations (4)

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf

HOP Jean Minjoz, Besançon

HOP d'Angers, Angers

Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle